bevacizumab (Avastin®, Genentech, Inc., San Francisco, CA, USA), a humanized monoclonal antibody against VEGFA, is currently the most promising GBM adjuvant therapy [26, 31]. This evidence concerns the gene VEGFA and glioblastoma.